Phase 3 validated Tag/Catcher cVLP display platform
AdaptVac's iso-peptide display platform utilises our proprietary MoonCatcher/Tag pair.
​
Furthermore, the cVLP is based on Tag or Catcher fused Bacteriophage AP205 capsid protein, which spontaneously forms a capsid Virus-Like Particle during production in E.coli.
​
MoonCatcher and AP205 have now been through Phase 3 clinical testing in our ABNCoV2 COVID-19 vaccine program.
Demonstrating safety, scalability, as well as EU and US regulatory acceptance for our platform.
Merel J Smit, et al. First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2.
Lancet Microbe. doi: https://doi.org/10.1016/S2666-5247(22)00337-8
​
Ximba P, et al.. Development of a synthetic nanoparticle vaccine presenting the HIV-1 envelope glycoprotein.
Nanotechnology. 2022 Jul 26. doi: 10.1088/1361-6528/ac842c.
Linda van Oosten, et al. An S1-nanoparticle vaccine protects against SARS-CoV-2 challenge in K18-hACE2 mice.
J Virol. 2022 Jul 27;96(14):e0084422. doi: 10.1128/jvi.00844-22.
Jannick Prentoe, et al. Two-component Vaccine Consisting of Virus-Like Particles Displaying Hepatitis C Virus Envelope Protein 2 Oligomers. npjVvaccines (accepted). 2022.
Kara-Lee Aves, et al. Freeze-drying of a capsid virus-like particle-based platform allows stable storage of vaccines at ambient temperature. Pharmaceutics 14 (6), 1301. 2022
Goksøyr L, et al. Preclinical Efficacy of a Capsid Virus-like Particle-Based Vaccine Targeting IL-1β for Treatment of Allergic Contact Dermatitis.
Vaccines. 2022 May 23;10(5):828. doi:10.3390/vaccines10050828
Volkmann A, et al.. A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus Macaques.
Front Immunol. 2022 Apr 5;13:857440. doi: 10.3389/fimmu.2022.857440
Azad Farzadfard at al.. The C-terminal tail of α-synuclein protects against aggregate replication but is critical for oligomerization.
Communications Biology. 2022 Feb 10;5(1):123. doi: 10.1038/s42003-022-03059-8.2022.
van Oosten et al. Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants.
mBio. 2021 Oct 26;12(5):e0181321. doi: 10.1128/mBio.01813-21. Epub 2021 Oct 12. PMID: 34634927; PMCID: PMC8510518.
Jitthamstaporn et al Virus-like particles displaying recombinant Der p 1 allergen to optimize IgG blocking antibody response.
Allergy. 2021 Oct 7. doi: 10.1111/all.15129. Epub ahead of print. PMID: 34617292.
Fredsgaard et al.. Head-to-Head Comparison of Modular Vaccines Developed Using Different Capsid Virus-Like Particle Backbones and Antigen Conjugation Systems. Vaccines (Basel). 2021 May 21;9(6):539. doi: 10.3390/vaccines9060539. PMID: 34063871; PMCID: PMC8224050.
Janitzek et al. The Immunogenicity of Capsid-Like Particle Vaccines in Combination with Different Adjuvants Using Different Routes of Administration.
Vaccines. 2021 Feb 6;9(2):131. doi: 10.3390/vaccines9020131. PMID: 33562114; PMCID: PMC7915698.
Fougeroux et al. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity.
Nat Commun. 2021 Jan 12;12(1):324. doi: 10.1038/s41467-020-20251-8. PMID: 33436573; PMCID: PMC7804149.
Thrane et al. A Vaccine Displaying a Trimeric Influenza-A HA Stem Protein on Capsid-Like Particles Elicits Potent and Long-Lasting Protection in Mice.
Vaccines. 2020 Jul 15;8(3):389. doi: 10.3390/vaccines8030389. PMID: 32679905; PMCID: PMC7564254.
Harmsen et al. Immunization with virus-like particles conjugated to CIDRα1 domain of Plasmodium falciparum erythrocyte membrane protein 1 induces inhibitory antibodies.
Malar J. 2020 Mar 30;19(1):132. doi: 10.1186/s12936-020-03201-z. PMID: 32228596; PMCID: PMC7106694.
Aves et al. Advantages and Prospects of Tag/Catcher Mediated Antigen Display on Capsid-Like Particle-Based Vaccines. Viruses. 2020 Feb 6;12(2):185. doi: 10.3390/v12020185. PMID: 32041299; PMCID: PMC7077247.
Soongrung et al. Virus-like particles displaying major house dust mite allergen Der p 2 for prophylactic allergen immunotherapy.
Allergy. 2020 May;75(5):1232-1236. doi: 10.1111/all.14096. Epub 2020 Feb 5. PMID: 31701528.
Singh et al. Pf/is230 and Pfis48/45 Fusion Proteins Elicit Strong Transmission-Blocking Antibody Responses Against Plasmodium falciparum. Front Immunol. 2019 Jun 5;10:1256. doi: 10.3389/fimmu.2019.01256. PMID: 31231386; PMCID: PMC6560166.
Janitzek et al. A proof-of-concept study for the design of a VLP-based combinatorial HPV and placental malaria vaccine.
Sci Rep. 2019 Mar27;9(1):5260. doi: 10.1038/s41598-019-41522-5. PMID: 30918267; PMCID: PMC6437161.
Sander et al. Virus-like antigen display for cancer vaccine development, what is the potential?
Expert Rev Vaccines. 2018 Apr;17(4):285-288. doi: 10.1080/14760584.2018.1455505. Epub 2018 Mar 30. PMID: 29560746.
Palladini et al.. Virus-like particle display of HER2 induces potent anti-cancer responses.
Oncoimmunology. 2018 Jan 5;7(3):e1408749. doi: 10.1080/2162402X.2017.1408749. PMID: 29399414; PMCID: PMC5790387.
Singh et al. Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.
Vaccine. 2017 Jun 27;35(30):3726-3732. doi: 10.1016/j.vaccine.2017.05.054. Epub 2017 May 31. PMID: 28578824.
Janitzek et al. Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses.
Malar J. 2016 Nov 8;15(1):545. doi: 10.1186/s12936-016-1574-1. PMID: 27825348; PMCID: PMC5101663.
Thrane et al. Bacterial superglue enables easy development of efficient virus-like particle based vaccines. J Nanobiotechnology. 2016 Apr 27;14:30. doi: 10.1186/s12951-016-0181-1. PMID: 27117585; PMCID: PMC4847360.
Thrane et al. A Novel Virus-Like Particle Based Vaccine Platform Displaying the Placental Malaria Antigen VAR2CSA. PLoS One. 2015 Nov 23;10(11):e0143071. doi: 0.1371/journal.pone.0143071. PMID: 26599509; PMCID: PMC4657905.
Chapter: “Design and purification of Tag/Catcher AP205-based capsid virus-like particle vaccines”. Authors: Kara-Lee Aves and Adam F. Sander for "Therapeutic Proteins: Methods and Protocols" published in Methods in Molecular Biology, Springer Nature (in press).
Louise et al. A capsid-based virus-like particle vaccine displaying full-length PCSK9 lowers plasma PCSK9 levels compared to vaccines displaying PCSK9-derived peptide antigens. Nanomedicine (in review).
Ruzzi et al. Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine. Biomedicines. 2022; 10(10):2654
​
​